E-109 Short-term in-hospital outcomes of thrombolysis for acute ischemic stroke patients with non-primary brain tumors and electrolyte imbalances

Raymond Kai‐Yu Tong, A Wang-Selfridge, Patrick M. Brauer2019 · DOI

Abstract

Intravenous thrombolysis is a critical but underutilized treatment for acute ischemic stroke (AIS), often due to various contraindications. While previous research has explored the safety of thrombolysis in patients with benign brain tumors, the impact of metabolic disturbances like electrolyte imbalances (EI) remains less understood. This retrospective cohort study analyzed data from the Nationwide Inpatient Sample (2012–2015Q3) to evaluate short-term outcomes for AIS patients without primary brain tumors who received thrombolysis. The study found that patients with concurrent electrolyte imbalances experienced significantly higher mortality rates, longer hospital stays, and increased inpatient charges compared to those without imbalances. These findings suggest that managing electrolyte levels may be a vital component of improving outcomes for stroke patients undergoing thrombolytic therapy.

Introduction

Acute ischemic stroke (AIS) requires rapid intervention to minimize neuronal damage, with intravenous thrombolysis serving as the gold standard for pharmacological reperfusion. However, the clinical decision to administer "clot-busting" agents is often complicated by a patient’s underlying physiological state. While the medical community has gained clarity on treating stroke patients with certain comorbidities, such as benign brain tumors, the influence of common metabolic disturbances—specifically electrolyte imbalances—has been less scrutinized.

Electrolyte imbalances (disturbances in sodium, potassium, calcium, etc.) are frequent in acute care settings and can reflect systemic frailty or acute physiological stress. This study aims to investigate whether these imbalances serve as significant predictors of poor short-term outcomes in AIS patients receiving thrombolysis, specifically focusing on those without a history of primary brain tumors.

Methods

The researchers conducted a retrospective cohort study utilizing the Nationwide Inpatient Sample (NIS), the largest publicly available all-payer inpatient database in the United States. The study period spanned from 2012 through the third quarter of 2015.

Population Selection and Filtering

Adult patients (ages 18+) who suffered an AIS and received intravenous thrombolysis were identified using ICD-9 codes. To isolate the impact of electrolyte imbalances, the researchers applied several exclusion criteria:

  • Patients with primary brain tumors (both benign and malignant) were excluded.
  • Patients missing critical clinical identifiers (age, gender, race, or mortality data) were removed.
  • Patients who did not receive IV thrombolysis were excluded.

Data Analysis

The final cohort was divided into two groups: those diagnosed with electrolyte imbalances (EI) and those without. The primary metrics assessed included hospital mortality rates, length of stay (LOS), total inpatient charges, and average age at admission.

Results

The study analyzed a total of 24,692 patient encounters. Within this group, 5,450 patients (approximately 22%) were diagnosed with electrolyte imbalances. The statistical analysis revealed significant disparities across all measured outcomes:

  • Mortality Rate: Patients with EI faced a mortality rate of 10.4%, nearly double the 6.0% observed in patients without EI (p < 0.0001).
  • Length of Stay (LOS): The mean LOS was significantly longer for the EI group (9.21 days) compared to the non-EI group (5.53 days) (p < 0.0001).
  • Total Hospital Charges: Average charges were substantially higher for patients with EI ($117,906.49) than for those without ($77,032.77) (p < 0.0001).
  • Age at Admission: Patients with EI were slightly but significantly older on average (67.88 years vs. 66.81 years) (p < 0.0001).

Discussion

The findings indicate that electrolyte imbalance is a potent "risk multiplier" in the context of acute stroke and thrombolysis. The jump in mortality from 6% to over 10% is clinically massive, suggesting that metabolic disturbances may either exacerbate the brain's vulnerability to ischemia or serve as markers for more severe systemic complications.

The "Metabolic Tax"

The data reveals a significant "metabolic tax" associated with EI. Patients with imbalances stayed in the hospital nearly four days longer and incurred approximately $40,000 more in charges. This suggests that EI may complicate the initial recovery phase or indicate a level of physiological frailty that necessitates more intensive, and thus more expensive, inpatient care. The correlation with older age further supports the idea that these patients may have less physiological reserve, making them more susceptible to dehydration or renal issues that precipitate electrolyte shifts.

Conclusion and Future Directions

This study highlights the critical importance of metabolic management in the emergency treatment of stroke. For physicians, the presence of electrolyte imbalances should be viewed as a significant red flag that requires clinical attention. The findings suggest that placing a greater focus on stabilizing electrolyte levels before or during the administration of IV thrombolysis could potentially improve short-term in-hospital outcomes.

Limitations

As a retrospective study based on ICD-9 administrative coding, the research is limited by the potential for entry errors and a lack of granular detail regarding the specific type or severity of the electrolyte imbalances.

Future Research

Future studies should investigate whether the relationship between EI and poor outcomes is strictly causal or if EI is merely a proxy for stroke severity. Additionally, prospective trials are needed to determine if rapid metabolic correction can alter the prognosis for these patients. Finally, research into different thrombolytic agents (such as Tenecteplase) may reveal if certain medications are more optimal for patients presenting with metabolic disturbances.

Summary updated

Abstract

<h3>Background</h3> Intravenous thrombolysis remains an underutilized treatment for acute ischemic stroke (AIS) due to several relative and absolute contraindications. Previous studies have found similar outcomes after thrombolysis between AIS patients with benign brain tumors and AIS patients without. This study aims to investigate short-term outcomes of thrombolytic treatment for the greater majority of AIS patients who have no history of primary brain tumors, particularly those with electrolyte imbalances. <h3>Methods</h3> This retrospective cohort study utilized data from the 2012–2015Q3 Nationwide Inpatient Sample (NIS). ICD-9 codes identified adult patients (ages 18+) who suffered acute ischemic stroke and received intravenous thrombolysis, and then further isolated patients diagnosed with electrolyte imbalances. Data for patients who were missing important clinical identifiers (age, gender, race, mortality), did not receive IV thrombolysis, and had primary brain tumors (benign or malignant) were excluded. Data analyses assessed hospital mortality rate, length of stay (LOS), inpatient charges, and average age of admission. <h3>Results</h3> Of the 24692 encounters with AIS patients treated with thrombolysis and had no history of primary brain tumors, 5450were diagnosed with electrolyte imbalances (EI). Mean mortality rate of patients was significantly increased (10.4% with EI vs. 6.0% with no EI, p&lt;0.0001). Mean LOS was significantly longer (9.21 days with EI vs. 5.53 days with no EI, p&lt;0.0001). Average total charges were significantly increased ($117,906.49 with EI vs. $77,032.77 with no EI, p&lt;0.0001). Average age at admission was significantly older (67.88 years with EI vs. 66.81 years with no EI, p&lt;0.0001) <h3>Conclusion</h3> This study aims to inform physicians to better manage AIS patients receiving IV thrombolysis with electrolyte imbalances and no history of primary brain tumors. These patients experience higher mortality rate, longer LOS, increased total hospital charges, and older age at admission than those without EI. These findings suggest that placing clinical focus on managing electrolyte imbalances before administering IV thrombolysis for AIS may be critical for improving short-term in-hospital outcomes. Future research should aim to investigate different thrombolytic agents to determine the most optimal choice for patients with electrolyte imbalances. <h3>Disclosures</h3> <b>K. Tong:</b> None. <b>A. Wang-Selfridge:</b> None. <b>P. Brauer:</b> None.
BibTeX
@misc{tong2019e,
  author = {Raymond Kai‐Yu Tong and A Wang-Selfridge and Patrick M. Brauer},
  title = {{E-109 Short-term in-hospital outcomes of thrombolysis for acute ischemic stroke patients with non-primary brain tumors and electrolyte imbalances}},
  year = {2019},
  doi = {10.1136/neurintsurg-2019-snis.184},
}
Figure